Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28506151 | 0.90 | HDAC4 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2732349 | 0.85 | CA1 (0.54) | PIK3CACA1CA2CA9NAMPT | |
| SCHEMBL28513866 | 0.83 | LIPG (0.40) | CA1CA2CA9CA12CA3 | |
| SCHEMBL31144570 | 0.81 | POLB (0.57) | CA1CA2CA9NAMPTHRH3 | |
| SCHEMBL22922489 | 0.80 | HDAC4 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL628455 | 0.79 | LSS (0.52) | MTORPIK3CACA1CA2CA9 | |
| SCHEMBL628548 | 0.79 | HRH3 (0.62) | MTORPIK3CACA1CA2CA9 | |
| SCHEMBL14942938 | 0.79 | CA1 (0.57) | CA1CA2CA9CXCR2PDGFRB | |
| SCHEMBL22084735 | 0.78 | TERT (0.49) | CA1CA2CA9CXCR2CA12 | |
| SCHEMBL8611816 | 0.77 | PIK3CA (0.54) | MTORPIK3CAPIK3CGMCHR1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115092-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115092-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115092-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012058671-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | MTOR 1/4885PIK3CA 2/4885PIK3CG 10/4885 |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | MTOR 1/4885PIK3CA 2/4885PIK3CG 10/4885 |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | MTOR 1/4885PIK3CA 2/4885PIK3CG 10/4885 |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | MTOR 1/4885PIK3CA 2/4885PIK3CG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.